Coordinated modulation of epigenetic profile of CXCL1-8 genes with corresponding downregulation of gene expression and protein levels, and inhibition of immune cell recruitment, shown in multiple models of inflammatory disease Demonstrates OMEGA platform’s ability to prospectively engineer programmable mRNA candidates to enable multiplexing for controlled epigenomic modulation CAMBRIDGE, Mass., Oct.

在多种炎性疾病模型中显示CXCL1-8基因的表观遗传谱的协调调节与相应的基因表达和蛋白质水平的下调以及免疫细胞募集的抑制表明OMEGA平台能够前瞻性地设计可编程mRNA候选物以实现多重控制表观基因组调制剑桥，马萨诸塞州。，Oct。

31, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced new preclinical data showcasing simultaneous and coordinated pre-transcriptional control of multiple genes co-located in an insulated genomic domain (IGD) by a single epigenomic controller (EC) at the 11th International mRNA Health Conference taking place in Berlin, Germany, October 31 – November 2, 2023.

312023（GLOBE NEWSWIRE）-欧米茄治疗公司（纳斯达克股票代码：OMGA）（“欧米茄”），一家临床阶段生物技术公司，开创了一类新型可编程表观基因组mRNA药物的开发，今天宣布了新的临床前数据，展示了在德国柏林举行的第11届国际mRNA健康会议上，通过单一表观基因组控制器（EC）同时协调的位于绝缘基因组结构域（IGD）中的多个基因的转录前控制，2023年10月31日至11月2日。

“These new preclinical data show that, through deep understanding of disease biology and genomic architecture, our OMEGA platform is able to design a programmable mRNA candidate capable of multiplexing to pre-transcriptionally control the expression of multiple genes in preclinical models,” said Thomas McCauley, Ph.D., Chief Scientific Officer of Omega Therapeutics.

“这些新的临床前数据表明，通过深入了解疾病生物学和基因组结构，我们的OMEGA平台能够设计一种可编程的mRNA候选物，能够多路复用以转录前控制临床前模型中多种基因的表达，”欧米茄治疗学首席科学官Thomas McCauley博士说。

“By targeting a genomic locus containing a cluster of cytokine genes, we can precisely modulate immune activity to elicit a meaningful anti-inflammatory response. The potential applications of this strategy extend beyond any single disease and highlight the broad potential of precision epigenomic control.” Details for the poster presentation:Title: Design and Characterization of a Programmable Epigenomic Controller Demonstrating Multiplexed Targeting of the CXCL1-8 Gene Cluster for Treatment of.

“通过靶向含有一组细胞因子基因的基因组位点，我们可以精确调节免疫活性以引发有意义的抗炎反应。该策略的潜在应用超越了任何单一疾病，突出了精确表观基因组控制的广泛潜力。海报展示的细节：标题：可编程表观基因组控制器的设计和表征，展示CXCL1-8基因簇的多重靶向治疗。